155 related articles for article (PubMed ID: 38443968)
1. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
Hu Y; Revenko A; Barsoumian H; Bertolet G; Fowlkes NW; Maazi H; Green MM; He K; Sezen D; Voss TA; Leyton CSK; Masrorpour F; Rafiq Z; Puebla-Osorio N; Leuschner C; MacLeod R; Cortez MA; Welsh JW
J Exp Clin Cancer Res; 2024 Mar; 43(1):70. PubMed ID: 38443968
[TBL] [Abstract][Full Text] [Related]
2. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model.
Hu Y; Paris S; Bertolet G; Barsoumian HB; Wang Q; Da Silva J; Patel NB; Nguyen N; Doss DJ; Huang A; Hsu E; Leyton CSK; Voss TA; Masrorpour F; Leuschner C; Pietz JT; Puebla-Osorio N; Gandhi S; Nguyen QN; Wang J; Cortez MA; Welsh JW
Front Immunol; 2022; 13():1022011. PubMed ID: 36405757
[TBL] [Abstract][Full Text] [Related]
3. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
[TBL] [Abstract][Full Text] [Related]
4. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
[TBL] [Abstract][Full Text] [Related]
5. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.
Hu Y; Paris S; Bertolet G; Barsoumian HB; He K; Sezen D; Chen D; Wasley M; Silva JD; Mitchell JA; Voss TA; Masrorpour F; Leyton CK; Yang L; Leuschner C; Puebla-Osorio N; Gandhi S; Nguyen QN; Cortez MA; Welsh JW
J Nanobiotechnology; 2022 Sep; 20(1):417. PubMed ID: 36123677
[TBL] [Abstract][Full Text] [Related]
6. Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer.
Myers Chen KV; de Groot AE; Mendez SA; Mallin MM; Amend SR; Pienta KJ
Med Oncol; 2023 Aug; 40(10):284. PubMed ID: 37644281
[TBL] [Abstract][Full Text] [Related]
7. Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy.
Tormoen GW; Blair TC; Bambina S; Kramer G; Baird J; Rahmani R; Holland JM; McCarty OJT; Baine MJ; Verma V; Nabavizadeh N; Gough MJ; Crittenden M
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):93-103. PubMed ID: 32311417
[TBL] [Abstract][Full Text] [Related]
8. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model.
Hu Y; Paris S; Barsoumian H; Abana CO; He K; Sezen D; Wasley M; Masrorpour F; Chen D; Yang L; Dunn JD; Gandhi S; Nguyen QN; Cortez MA; Welsh JW
J Nanobiotechnology; 2021 Dec; 19(1):416. PubMed ID: 34895262
[TBL] [Abstract][Full Text] [Related]
9. MerTK as a therapeutic target in glioblastoma.
Wu J; Frady LN; Bash RE; Cohen SM; Schorzman AN; Su YT; Irvin DM; Zamboni WC; Wang X; Frye SV; Ewend MG; Sulman EP; Gilbert MR; Earp HS; Miller CR
Neuro Oncol; 2018 Jan; 20(1):92-102. PubMed ID: 28605477
[TBL] [Abstract][Full Text] [Related]
10. Differential polarization and the expression of efferocytosis receptor MerTK on M1 and M2 macrophages isolated from coronary artery disease patients.
Mohd Idrus FN; Ahmad NS; Hoe CH; Azlan M; Norfuad FA; Yusof Z; Wan Isa WYH; Mohamed Ali AA; Yvonne-Tee GB
BMC Immunol; 2021 Mar; 22(1):21. PubMed ID: 33761885
[TBL] [Abstract][Full Text] [Related]
11. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
[TBL] [Abstract][Full Text] [Related]
12. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Zhou Y; Fei M; Zhang G; Liang WC; Lin W; Wu Y; Piskol R; Ridgway J; McNamara E; Huang H; Zhang J; Oh J; Patel JM; Jakubiak D; Lau J; Blackwood B; Bravo DD; Shi Y; Wang J; Hu HM; Lee WP; Jesudason R; Sangaraju D; Modrusan Z; Anderson KR; Warming S; Roose-Girma M; Yan M
Immunity; 2020 Feb; 52(2):357-373.e9. PubMed ID: 32049051
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer.
He K; Barsoumian HB; Puebla-Osorio N; Hu Y; Sezen D; Wasley MD; Bertolet G; Zhang J; Leuschner C; Yang L; Kettlun Leyton CS; Fowlkes NW; Green MM; Hettrick L; Chen D; Masrorpour F; Gu M; Maazi H; Revenko AS; Cortez MA; Welsh JW
Cancer Immunol Res; 2023 Apr; 11(4):486-500. PubMed ID: 36700864
[TBL] [Abstract][Full Text] [Related]
15. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer.
Oweida AJ; Darragh L; Phan A; Binder D; Bhatia S; Mueller A; Court BV; Milner D; Raben D; Woessner R; Heasley L; Nemenoff R; Clambey E; Karam SD
J Natl Cancer Inst; 2019 Dec; 111(12):1339-1349. PubMed ID: 30863843
[TBL] [Abstract][Full Text] [Related]
16. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
Kostecki KL; Iida M; Wiley AL; Kimani S; Mehall B; Tetreault K; Alexandridis R; Yu M; Hong S; Salgia R; Bruce JY; Birge RB; Harari PM; Wheeler DL
Head Neck; 2023 May; 45(5):1255-1271. PubMed ID: 36939040
[TBL] [Abstract][Full Text] [Related]
17. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory.
Sezen D; Barsoumian HB; He K; Hu Y; Wang Q; Abana CO; Puebla-Osorio N; Hsu EY; Wasley M; Masrorpour F; Wang J; Cortez MA; Welsh JW
Front Immunol; 2022; 13():984318. PubMed ID: 36275767
[TBL] [Abstract][Full Text] [Related]
18. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
19. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Cook RS; Jacobsen KM; Wofford AM; DeRyckere D; Stanford J; Prieto AL; Redente E; Sandahl M; Hunter DM; Strunk KE; Graham DK; Earp HS
J Clin Invest; 2013 Aug; 123(8):3231-42. PubMed ID: 23867499
[TBL] [Abstract][Full Text] [Related]
20. SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Chen D; Barsoumian HB; Yang L; Younes AI; Verma V; Hu Y; Menon H; Wasley M; Masropour F; Mosaffa S; Ozgen T; Klein K; Cortez MA; Welsh JW
Cancer Immunol Res; 2020 Jul; 8(7):883-894. PubMed ID: 32299915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
